ritonavir and Neutropenia

ritonavir has been researched along with Neutropenia* in 3 studies

Trials

1 trial(s) available for ritonavir and Neutropenia

ArticleYear
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    The Pediatric infectious disease journal, 2014, Volume: 33, Issue:9

    Twice-daily darunavir/ritonavir is indicated in treatment-experienced children (≥3 years). This study assessed once-daily administration in treatment-naïve adolescents.. Phase 2, 48-week, open-label, single-arm study evaluating pharmacokinetics, safety and efficacy of once-daily darunavir/ritonavir 800/100 mg in treatment-naïve, HIV-1-infected adolescents (≥12 to <18 years, ≥40 kg) with zidovudine/lamivudine or abacavir/lamivudine.. Twelve patients (67% female; median 14.4 years) were enrolled. After 24 and 48 weeks, respectively, 11 of 12 (92%) and 10 of 12 (83%) patients achieved viral load <50 copies/mL (intent-to-treat time-to-loss of virologic response); all had ≥1 log10 drop in viral load versus baseline. Median CD4 cell count increased by 175 and 221 cells/mm (intent-to-treat-noncompleter = failure) after 24 and 48 weeks, respectively. Eighty-three percent of patients were adherent to darunavir/ritonavir. One patient was never suppressed and 1 patient rebounded. No patients developed darunavir resistance-associated mutations or lost phenotypic susceptibility to any commercially available protease inhibitor or any background nucleoside reverse transcriptase inhibitor. Eleven patients (92%) reported ≥1 adverse event (AE), considered in 2 patients to be at least possibly related to darunavir (gastrointestinal-related events and dizziness). Four patients had ≥1 serious AE. Three patients reported ≥1 grade 3/4 AE; no serious or grade 3/4 AEs were considered darunavir related. No patients discontinued because of AEs.. Over 48 weeks, once-daily darunavir/ritonavir 800/100 mg plus NRTIs was effective and well-tolerated for treatment of HIV-1-infected, antiretroviral-naïve adolescents (≥12 to <18 years). These findings support use of once-daily darunavir/ritonavir 800/100 mg in this population.

    Topics: Adolescent; Anemia; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Nausea; Neutropenia; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Time Factors; Viral Load; Vomiting; Zidovudine

2014

Other Studies

2 other study(ies) available for ritonavir and Neutropenia

ArticleYear
Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients.
    British journal of clinical pharmacology, 2010, Volume: 69, Issue:1

    Topics: Adult; Antineoplastic Agents; Docetaxel; Drug Interactions; Exanthema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mucositis; Neutropenia; Ritonavir; Seizures, Febrile; Taxoids

2010
Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma.
    AIDS (London, England), 2008, Jun-19, Volume: 22, Issue:10

    Topics: Adult; Antineoplastic Agents; Contraindications; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Drug Therapy, Combination; Eyelid Neoplasms; HIV Infections; HIV Protease Inhibitors; Humans; Male; Neutropenia; Ritonavir; Sarcoma, Kaposi; Taxoids

2008